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ABSTRACT: 5 
AIM: To explore UK professionals’ interpretations of medicines optimisation and expansion 6 
of nurses’ roles. 7 
DESIGN: This mixed-methods study sought professionals’ views on nurses’ involvement, 8 
competency, and engagement in: monitoring patients for adverse effects of medicines, 9 
monitoring adherence, prescribing, and patient education. 10 
METHOD: An online survey and interviews were undertaken with nurses, doctors and 11 
pharmacists in Wales and England, May 2018 to July 2019.  12 
RESULTS: In all, 220 nurses, 17 doctors and 62 pharmacists responded to the online survey, 13 
and 24 professionals were interviewed. Nurses were divided over extending their roles, with 14 
123/220 (55.9%) wishing to extend roles in monitoring patients for possible adverse drug 15 
reactions (ADRs), 111/220 (50.5%) in adherence monitoring, 121/220 (55.0%) in prescribing, 16 
and 122/220 (55.4%) in patient education. The best-qualified nurses were the most willing 17 
to increase involvement in monitoring patients for ADRs (aOR 13.00, 1.56-108.01). 18 
Interviews revealed that both nurses and doctors assumed the other profession was 19 
undertaking this monitoring. Respondents agreed that increasing nurses’ involvement in 20 
medicines optimisation would improve patient care, but expressed reservations regarding 21 
nurses’ competencies.  Collaboration between nurses and doctors was suboptimal (rated 22 
7/10 at best), and between nurses and pharmacists even more so (6/10 at best).  23 
CONCLUSION: Juxtaposition of datasets identified problems with medicines optimisation: 24 
although most respondents agreed that increasing nurses’ involvement would positively 25 
impact practice, their educational preparation was a barrier. Only ~50% of nurses were 26 
willing to expand their roles to fill the hiatus in care identified and ensure that at least one 27 
profession was taking responsibility for ADR monitoring. 28 
IMPACT: To improve multi-professional team-working and promote patient safety, nurse 29 
leaders should ensure patients are monitored for possible ADRs by at least one profession. 30 
Initiatives expanding nurses’ roles in medicines optimisation and prescribing might be best 31 
targeted towards the more educated nurses, who have multidisciplinary support. 32 
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Nurses’ contributions to medicines optimisation: 1 
a mixed methods study 2 
1 | INTRODUCTION 3 
The scale and complexity of inadvertent iatrogenic harm from the use and misuse of 4 
medicines underlie the World Health Organisation’s (WHO) Third Global Patient Safety 5 
Challenge - to reduce avoidable medication-related harm by 50% by 2022 (WHO, 2017). To 6 
address this issue, medicines management, optimisation and pharmaceutical care must be 7 
prioritised. This study explores professionals’ interpretations of 4 key aspects of medicines 8 
management and potential expansion of nurses’ roles in the UK. 9 
 10 
2| BACKGROUND 11 
Preventable adverse drug reactions and events (ADRs/ ADEs) have proved an intractable 12 
problem over the last decade, causing 5-8% of unplanned hospital admissions (National 13 
Institute for Clinical Excellence (NICE), 2015), rising to ~10-15% amongst older adults 14 
(Oscanoa, Lizaraso, & Carvajal, 2017), costing the UK NHS £1bn-2.5bn each year. Higher 15 
prevalence in larger, prospective studies (Alhawassi, Krass, Bajorek, & Pont, 2014), and non-16 
recognition of ~60% events suggest that these figures may be an underestimate (Roulet et 17 
al., 2014) and prevalences of 11% and 18% are quoted (Kongkaew et al., 2013, Rydberg et 18 
al., 2016). The problem is at least as extensive in developing countries, at ~10% of 19 
admissions (WHO, 2009), rising to 20% amongst older adults in Africa (Oscanoa et al, 2017). 20 
 21 
Most ADEs, ADRs (up to 92%), and medicines’ mismanagement (including errors by patients 22 
and professionals) are preventable (NICE, 2015), particularly with additional enhanced 23 
monitoring (Gabe et al, 2011; Gandhi et al., 2010). Outside hospital, 15 preventable ADEs 24 
occur each 1000 person-years, and 25% of these are serious (Gandhi et al., 2010). In 25 
hospitals, preventable, mainly dose-dependent and moderately severe, ADRs affect 3.13 in 26 
each 100 patients (95% CI 2.87-3.38, full range 0.006 to 13.3), with lower rates in studies 27 
relying on voluntary reporting (Oscanoa et al., 2017, Wolfe et al., 2018).  28 
 29 
Medicines optimisation (NICE, 2015) is a patient-focused approach to getting the best from 30 
investment in and use of medicines that requires a holistic approach, an enhanced level of 31 
patient centred professionalism, and partnership between clinical professionals and 32 
 4 
patients. Medicines optimisation and pharmaceutical care require multidisciplinary team 1 
working to an extent not previously encountered. Healthcare professionals need to work 2 
together to individualise care, monitor outcomes more carefully, review medicines more 3 
frequently and support patients (Royal Pharmacological Society (RPS), 2013). However, 4 
nurses’ contributions to medicines optimisation and pharmaceutical care remain 5 
unexplored.  6 
 7 
3 | THE STUDY 8 
3.1 | Aims 9 
Building on theories of division of labour (Jordan & Hughes 2002) and ‘orphaned tasks’ 10 
(Jordan 2002), we report on the readiness of nurses, doctors and pharmacists to engage and 11 
optimise four specific responsibilities: monitoring patients for adverse effects of their 12 
medicines, adherence to prescribed regimens, prescribing and patient education. 13 
 14 
3.2 | Design 15 
We explored nurses’, doctors’ and pharmacists’ interpretations of nurses’ roles in medicines 16 
optimisation and pharmaceutical care with a pragmatic mixed methods approach (Ford-17 
Gilboe, Cambell & Berman, 1995; Teddlie &  Taskhokkori, 2012), comprising a cross-18 
sectional online survey, followed by 24 semi-structured interviews to investigate actual 19 
performance, barriers and facilitators (University of California, 2012). We have implemented 20 
mixed methods to strengthen the overall study design through triangulation and 21 
complementary results of the combined methods (Bryman, 2006). Questions were designed 22 
concurrently: neither findings informed the data collection of the other (Jeffries et al, 2019). 23 
This paper reports on two UK countries, Wales and England, participating in a pan-European 24 
project (De Baetselier et al., 2020). The good reporting guidelines for mixed methods 25 
research (O’Cathain, Murphy & Nicholl, 2008; National Institutes of Health (NIH), 2018) 26 
were followed (Supporting File 1). All questions are reported. 27 
 28 
3.3 | Sample/participation 29 
We contacted the University Health Boards (UHBs), NHS Trusts and private providers in 30 
South West Wales and Southern England: the areas where we plan to implement our 31 
findings. The questionnaire was distributed through online links to survey as many 32 
 5 
healthcare professionals as possible. Interviewees were purposively sampled across acute, 1 
domiciliary, residential and mental health settings to explore nurses’ roles in practice. 2 
 3 
3.4 | Data collection 4 
In the 10-minute structured questionnaire,  all questions were closed, either dichotomous 5 
or ordinal polychotomous, with Likert-type scales, allowing for neutral responses (Nardi, 6 
2018).  7 
 8 
For interviews, we sought representative senior NHS practitioners with significant day-to 9 
day clinical and managerial responsibility. Private sector participants were sought via 10 
contact with local Nursing home managers and the associated general practitioners (GPs) 11 
and pharmacists. In Wales, we recruited from two UHBs  and other networks, in England, 12 
one Trust and private sector providers were approached.  Participant information was 13 
shared with professionals who expressed interest. Participants were asked about their 14 
perception of the strengths, weaknesses, opportunities and threats of medicines 15 
optimisation (see Supporting  File 2 for interview schedule). All interviews were digitally 16 
recorded, fully anonymised and professionally transcribed.  17 
 18 
3.5 | Ethical considerations 19 
The survey was approved by the relevant University ethics committees. As we were 20 
contacting healthcare professionals, the English NHS Trust required full IRAS (Integrated 21 
Research Application System) ethical approval, which was granted 9th February 2018 22 
(reference number 239960), and cleared by the University on 15th March. When 23 
governance checks had been completed (10th April), approval was sought from the R&D 24 
(Research and Development) departments in Wales, and received 11th May 2018. IRAS 25 
approval was sought for the interview study by application to Health and Care Research 26 
Wales, and approved 24th January 2019 (REC reference 19/HCRW/00). 27 
 
We anticipated minimal physical and emotional risks, as the probability of harm or 28 
discomfort was expected to be no higher than ordinarily encountered in participants’ daily 29 
lives. There were no questions of a personal or sensitive nature, and no identifying 30 
information was sought. Participants were informed of the study’s rationale, data collection 31 
 6 
methods and aims, the voluntary nature of participation, and their rights to withdraw 1 
consent without penalty. Informed consent was sought (electronically or in person) and 2 
opportunity was given to participants to ‘phone or email researchers . 3 
 4 
We either did not collect, or immediately deleted, all data relating to: names, dates of birth, 5 
locations, health, social, racial or ethnic origin, political opinions, religious or philosophical 6 
beliefs, or trade union membership. No genetic or biometric data, tissue samples, data 7 
concerning health or data concerning a natural person's sex life or sexual orientation were 8 
collected (Information Commissioner’s Office, 2012; MRC 2018). 9 
 Throughout data collection and handling the associated risks of disclosure were mitigated 10 
in accordance with General Data Protection Regulations (GDPR) 2018 (Medical Research 11 
Council, 2018).  12 
 13 
 3.6 | Data Analysis 14 
All survey variables were described. Ratings were taken as ordinal and compared using 15 
Kruskal Wallis’ independent samples tests (Altman, 1991). To explore the predictors of 16 
“willingness to extend nurses’ roles” in ADR monitoring, adherence, prescribing and 17 
education amongst the 220 nurse respondents, binary outcome variables were obtained by 18 
combining categories. The relationship between nurses’ education and willingness to extend 19 
their roles was explored using Χ2 for trend (Altman, 1991). Binary logistic regression models 20 
were constructed using backwards elimination likelihood ratio to select predictor variables. 21 
We accounted for sex, education, area of practice, patient population, country, and the 22 
number of pharmacists and doctors contacted daily. Age and length of experience were 23 
tested separately, due to their high collinearity. Data were analysed in the Statistical 24 
Package for Social Sciences (SPSS), version 25.0. 25 
 26 
Qualitative data were coded and emerging themes identified, as a rolling process (Jordan & 27 
Hughes 1998). Transcripts were analysed with a thematic approach, based on Braun and 28 
Clarke (2006), in six stages: familiarisation with the data; primary coding of data by applying 29 
code labels to the text (see Supporting  File 3 for examples); identification of themes and 30 
patterns; review of themes (with wider research team); detailed analysis and consideration 31 
of the relevant themes; and defining outcomes from all data collected. Data analysis and 32 
 7 
interpretation were discussed by the UK and European teams, and the final analysis reflects 1 
joint decisions. 2 
 3 
Survey and interview data were integrated around the four responsibilities and the division 4 
of labour within these responsibilities, taking a pragmatic perspective of complementary 5 
triangulation (Östlund, Kidd, Wengström & Rowa-Dewar, 2011), illustrated in Figure 1. Cross 6 
cutting themes from the four responsibilities were derived from the data (NIH, 2018; Foss & 7 
Ellefsen, 2002; Denzin, 2012).  8 
 9 
3.7 | Validity and reliability/rigour 10 
The combination of datasets addressing the same question established  triangulation of 11 
methods (Morse, 2015). Further triangulation across data sources (participants), location 12 
(England and Wales) and 2 teams of investigators enhanced transferability. To ensure inter-13 
rater reliability, stability and validity of our qualitative data analysis, one of the authors who 14 
was not actively involved in data collection (SJ) periodically compared data collected by 15 
other investigators, checking codes, integrity of the analysis and resolving variances through 16 
discussion, in a peer debriefing role (Creswell & Miller, 2000). Purposive sampling of 17 
practice areas, and congruence of findings with the team’s background knowledge of the 18 
area enhanced credibility (Polit & Beck 2016).  19 
The face validity of the survey questions was established by a consortium of nurse 20 
researchers and the survey was piloted with 17 nurses. to check its applicability and 21 
comparability in different health systems: no changes were needed. No technical problems 22 
were reported. The representativeness of the survey sample was checked against externally 23 
sourced demographic information. For responses regarding nurse/doctor collaboration, 24 
nurse/pharmacist collaborations, nurses’ competence and team communication, Cronbach’s 25 
alpha coefficients were: 0.90, 0.93, 0.81, and 0.90 respectively, (1 item for each of the 4 26 
tasks), indicating high internal consistency. Questionnaires that were <50% complete were 27 
excluded, as advised by American Association for public opinion research (AAPOR, 2016). 28 
  29 
4 | RESULTS  30 
4.1 | Response rate and recruitment 31 
 8 
Survey  1 
In all, 220 nurses, 17 doctors and 62 pharmacists gave useable responses to the online 2 
survey, with primary and secondary care evenly represented. In England 139 professionals 3 
responded from 1,978 possible contacts. In Wales, 169 professionals participated from the 4 
~6,000 in the participating UHB and 78 nurses in other networks. Excluding the 47 5 
questionnaires that were <50% complete left 299 valid responses (179 in Wales and 120 in 6 
England) (Fig 2).  7 
 8 
Demographic details are described in Supporting File 4 Table 1. A disproportionately high 9 
number of nurse respondents held MScs or PhDs (Wales: 29.5% and 9%, England: 19.5% and 10 
3% respectively); 22% (Wales) and 33% (England) of respondents were involved in either 11 
research or management.  12 
 13 
Interviews  14 
Between February and July 2019, of 14 invitations issued in England, 12 responded 15 
positively & 2 failed to respond (both pharmacists). In Wales, 40 professionals were 16 
approached: 25 responded positively & 15 negatively or not at all, despite repeated 17 
contacts. One respondent subsequently withdrew, unwell, and a substitute was found. No 18 
reasons for declining or not responding were given. We had no responses from the Wales 19 
PICRIS practices, who are funded to undertake research (National Institute for Social Care 20 
and Health Research, 2014).   21 
 22 
Interviewees’ experience varied between 30 years (nurse, care home manager) to 3 years 23 
(physician – acute care). All interviews were held in private rooms within the participants’ 24 
working environments. Interviews lasted between 19 and 31 minutes.   25 
 26 
4.2 | Monitoring patients for ADRs: “the bit that’s missing” 27 
Most nurses surveyed felt that monitoring patients for the adverse and therapeutic effects 28 
of medications was part of their role, but a third of doctors and pharmacists disagreed 29 
(Supporting File 4, Table 2a). Interviews revealed a bleaker picture, more congruent with the 30 
high proportion of admissions caused by preventable ADRs. Doctors thought nurses were 31 
responsible for monitoring patients:  32 
 9 
 1 
“You prescribe that but you would expect that the nurse would not give it if the blood 2 
pressure was really low.  Just like with things like painkillers, making sure they 3 
wouldn’t give it if there were signs of toxicity. … you’re putting a lot of trust down to 4 
the nurse that’s giving the medication that they will make the sensible decision … a 5 
very significant amount of responsibility for it.” (England doctor Acute care).  6 
 7 
Whereas, nurses thought this was the doctors’ responsibility:  8 
“I'm a firm believer that if you prescribe a drug, it is your responsibility to follow up to 9 
see whether the outcome is of benefit to the patient.  So I think the primary 10 
responsibility for a follow up should be with the prescriber. (England, Community 11 
nurse), and I think the physicians have to provide information and instruction to the 12 
nurses.” (Acute nurse Wales). 13 
 14 
A few respondents were aware of this hiatus in care and communications: “I suppose the bit 15 
that’s missing is the recording and feeding back part so that any changes can be made.” 16 
(Mental health nurse England) (Table 1). 17 
 18 
Nurses gave significantly higher ratings to their collaboration with doctors and pharmacists 19 
on monitoring ADRs than did the other professionals (Kruskal-Wallis test, Χ2 22.61, df 2, 20 
p<0.001 and Χ2 10.97, df 2, p 0.005 respectively). Overall, there was broad agreement that 21 
nurses’ involvement would have a positive impact on the quality of patients’ care, and 22 
nurses’ involvement in monitoring should be extended. However, interviews revealed an 23 
important caveat: respondents spontaneously raised nurses’ inadequate preparation in 24 
pharmacotherapeutics, congruent with nurses’ assessment of their own competence being 25 
significantly higher than that of other healthcare professionals (Χ2 28.69, df 2, p <0.001):  26 
 27 
“Nurses may lack knowledge, so that is a weakness - their drug knowledge. And the 28 
fact that they should be aware of what they’re administering, what they’re giving to 29 
the patient, that they should have an idea of what it is.” (Wales, Acute care nurse). 30 
 31 
 10 
Many (n=123/220) nurses felt that their roles should be extended to encompass more 1 
patient monitoring for ADRs (Supporting File 4, Table 3a). This willingness was associated 2 
with nurses’ education level, particularly doctoral qualification (Table 2). 3 
 4 
A minority of nurses reported they had never observed ADRs, poor medication adherence or 5 
inappropriate prescribing (Table 3). The 14 nurses who had never observed a ‘side effect’ 6 
ranged in experience from 0-45 years. Over a third of nurses and doctors did not work with 7 
any pharmacists in their daily clinical practice, and around 1 in 7 nurses could not get the 8 
help they needed from doctors and pharmacists. A substantial minority of professionals, 9 
particularly doctors, did not think that employers’ policies promoted inter-professional 10 
medicines management (Table 4). 11 
 12 
4.3 | Monitoring adherence: “Did we do everything we could?” 13 
Nurses gave significantly higher ratings to their collaboration with doctors on monitoring 14 
medication adherence than other professionals (Χ2 19.73, df 2, p<0.001). Their assessment 15 
of their own competence was also significantly higher, with pharmacists and doctors in 16 
Wales having the most reservations (Χ2 14.90, df 2, p=0.001). Most respondents, particularly 17 
in mental health, thought more should be done (Table 1, Supporting file 4, Table 3a): 18 
 19 
“…the burden of those frequent relapses all because they didn’t take their tablets. 20 
And did we do everything we could have to prevent that? No we didn’t.” (Wales, 21 
nurse, mental health) 22 
 Doctors agreed this was a role nurses were able to undertake (Table 1), and involvement in 23 
monitoring adherence to medication was viewed positively (Supporting File 4, Tables 2a, 24 
3a). The association between willingness to extend roles in monitoring adherence and nurse 25 
education did not reach statistical significance in adjusted analyses (Table 2). 26 
 27 
4.4 | Prescribing: “recipe for disaster” or “potentially the answer”?  28 
Nurses gave higher ratings to their collaboration with doctors on prescribing medication 29 
than did the other professionals (Χ2 8.15, df 2, p=0.02). Nurses assessed their own 30 
competence to prescribe more highly than did others, reaching borderline statistical 31 
significance: the differences were more noticeable in Wales than in England (Χ2 6.07, df 2, 32 
 11 
p=0.05). Comments included: “sometimes nurse prescribers can get drawn into roles that go 1 
beyond their competence (England, doctor, mental health). 2 
 3 
In Wales, 27% of nurses, 78% of doctors and 45% of pharmacists did not consider 4 
prescribing medicines to be part of nurses’ roles; in England, it was 31.5%, 62% and 35% 5 
(Supporting File 4, Table 2b). Although most nurses felt that prescribing was a component of 6 
their roles, only a minority were active prescribers (26% & 9% in Wales & England). With the 7 
exception of doctors in Wales, only a minority stated that extending nurses’ involvement 8 
would not be positive. Most nurses thought that their involvement in prescribing should be 9 
extended, while most doctors and pharmacists thought it should remain unchanged 10 
(Supporting File 4, Table 3b). Concerns related to the practicalities of multiple prescribers, 11 
with no-one in overall control and potential for interactions:  12 
 13 
“Within the prescribing, having several people given free range to prescribe I think is 14 
the sort of recipe for disaster in general regardless of who it is” (Wales, nurse, acute) 15 
and “It could become chaotic and therefore unsafe and that we could lose control, is 16 
the principal fear and therefore lead to prescribing practices that are unregulated, 17 
unsafe and not monitored.” (England, doctor, mental health). ” We lose control of 18 
prescribing costs.” (England, doctor, community).   19 
 20 
Other reservations concerned existing workloads, and the associated potential for error, 21 
whereas support for nurse prescribing centred on specialist roles (Table 1). Willingness to 22 
prescribe was predicted by working with pharmacists, rather than education (Table 2). 23 
 24 
4.4 | Patient education: “some [nurses] don’t know what the medication is used for.”  25 
Nurses gave higher ratings to their collaboration on providing patient education or 26 
information about medication use with doctors and pharmacists than did the other 27 
professionals (Χ2 8.86, df 2, p=0.01 and Χ2 8.87, df 2, p=0.01). Their assessment of their own 28 
competence was also significantly higher (Χ2 20.75, df 2, p<0.001) than experienced by other 29 
professionals:  30 
 31 
 12 
“Patient education and information varies between individuals and nursing homes, 1 
how competent the nurse is on that. Some of them don’t even know what the 2 
medication is used for so they wouldn’t be in a good position to. But all I can say, it 3 
varies, it all depends on individual, but the majority I have come across, I wouldn’t” 4 
(England, pharmacist, nursing home). 5 
 6 
 Most Welsh (80%) and English (62%) nurses thought that providing patient education or 7 
information about medication use was a part of nurses’ roles (Supporting File 4, Table 2b), 8 
and 73% of Welsh nurses and 60% of English nurses had provided this in the last month 9 
(Table 1). However, only around half (57% and 41%) felt qualified to do this and relied on 10 
information from others. Many doctors and pharmacists (44% of doctors and 25% of 11 
pharmacists, Supporting File 4, Table 2b) felt patient education was not a component of 12 
nurses’ roles. All professionals thought that the involvement of nurses in providing patient 13 
education or information about medication use should be extended (Supporting File 4, 14 
Table 3b): 15 
 16 
 “In terms of education, again I think nurses should, they have an opportunity more 17 
than doctors do to educate” (Wales, doctor, community). 18 
 19 
The association between willingness to extend roles in patient education and nurse 20 
education did not reach statistical significance in adjusted analyses. (Table 2).  21 
 22 
4.5 | Over-arching themes 23 
Complementary triangulation (Östund et al 2011) revealed cross-cutting themes across the 24 
4 tasks examined: care gaps, where no professional is undertaking the task, and each thinks 25 
the other does it; inadequate nurses’ education and workload, preventing them from taking 26 
on additional roles/education (Table 1). 27 
 28 
5 | DISCUSSION  29 
The nursing workforce is divided regarding role expansion, and a care gap has opened, 30 
leaving the monitoring of patients for possible ADRs, non-adherence and patient education 31 
unattended: doctors and nurses each think the other is or should be doing this work, leading 32 
 13 
to preventable ADRs (Jordan 2002), sometimes necessitating hospitalisation (NICE, 2015; 1 
Jordan & Hughes, 2019; George et al, 2019). We identified dissonance in the data: whilst 2 
there was consensus that nurses should expand their roles in these domains and tasks, only 3 
~50% nurses were willing to do this. Nurses gave significantly higher ratings than other 4 
professionals regarding their own competence and inter-professional collaborations in 5 
monitoring, adherence, prescribing and patient education, corroborated by interviewees’ 6 
concerns over nurses’ education and availability.  7 
  8 
5.1 Care gaps: Roles and Relationships “It’s that missing link”  9 
This study exposed gaps in care: essential tasks unfulfilled by any professionals – through 10 
practitioners’ inadvertent misconceptions and absence of structure in policy and 11 
management.  This could be rectified by expanding roles of nurses (Dilles et al., 2013; Jordan 12 
et al 2015) and pharmacists (RPS 2013) and mandating structure (Jordan et al., 2019).  13 
 14 
Compliance with manufacturers’ therapeutic monitoring recommendations falls short in up 15 
to 73% (n=284) patients (Ramia, & Zeeney 2014), and structured nurse-led patient 16 
monitoring addresses this problem (Jordan 2002; Dilles et al 2013; Jordan et al., 2015; Jones, 17 
Moyle & Jordan, 2016; Dijkstra et al 2018; Jordan et al., 2019;). Interviews indicated that 18 
this gap was, in part, attributable to dissonance in expectations: both doctors and nurses 19 
thought the other profession was monitoring patients for ADRs, adherence, and patient 20 
education. Pharmacists and doctors were often aware that this left problems unattended, 21 
including administration of anti-hypertensives to people with hypotension or laxatives to 22 
patients with diarrhoea (Table 1) (Jordan et al., 2019). Most (90%) nurses agreed that 23 
monitoring is a component of nursing roles that would benefit patients (95%), and some 24 
55% of nurses were willing to address this gap by expanding their roles (Jordan, Logan, 25 
Panes, Vaismoradi, & Hughes, 2018). 26 
 27 
A similar proportion (55%) of nurses wished to expand their roles to encompass prescribing. 28 
Support from pharmacists predicted nurses’ willingness to prescribe (Creedon, Byrne, 29 
Kennedy, & McCarthy, 2015). Proponents mainly cited prescribing as a component of 30 
specialist roles, whereas detractors indicated that risk of errors increases when more than 31 
one professional is involved (Assiri et al., 2018), accounting for their reservations.  32 
 14 
 1 
As the professionals with the most contact with patients, nurses should engage patients in 2 
discussions around their medication regularly (Nursing and Midwifery Council (NMC), 2018a, 3 
2018b; Flanders 2018, Bowen, Rotz, Patterson, & Sen 2017), but only the more educated 4 
nurses were willing to monitor or educate patients. Many nurses (38/149, 26%) did not feel 5 
qualified to educate patients about their medicines, and their competence was rated no 6 
more highly for patient education than for prescribing.  7 
  8 
5.2 A workforce divided by education  9 
Although many nurses were willing to expand their roles, some of their colleagues were 10 
unconvinced of their competence, particularly in prescribing. Similar discrepancies were 11 
reported >40 years ago (Wilson, 1975). Some of these concerns would be allayed by 12 
national curricula specifying academic and clinical standards in pharmacology (Jordan, 13 
Davies, & Green, 1999) compatible with the needs of service users with multiple 14 
comorbidities and associated polypharmacy.  15 
 16 
A minority of nurses (6%) had never observed an ADR, despite prevalence of severe 17 
preventable events of 0.4% in primary care (Gandhi et al., 2010), 3.13% in secondary care 18 
(Oscanoa et al., 2017), and 100% prevalence of medicine-related problems (Jordan et al., 19 
2015; Jordan et al., 2019; Jones et al., 2016). The prevalence of prescribing errors ranges 20 
from 2 to 94% of prescriptions (Assiri et al., 2018), so it is surprising that any respondents in 21 
the online survey had never seen a prescribing error. 22 
 23 
All nurses interviewed and ~50% of nurses responding to the survey felt their roles should 24 
be extended to improve medicines optimisation, prevent ADRs and minimise iatrogenic 25 
harm, but barriers of education and time constraints were apparent. The 2019 changes in 26 
the preregistration nursing curriculum may increase nurses’ engagement (Nursing & 27 
Midwifery standards 2018; Nursing & Midwifery Council, 2018) ; however, the uptake of 28 
current nurse prescribing initiatives is suboptimal (Drennan, Grant & Harris, 2014). Our data 29 
indicate that, to succeed, role expansion should be targeted towards better-educated and 30 
motivated nurses: role expansion in medicines optimisation may not be for all nurses, and 31 
this should be recognised as initiatives are rolled out. 32 
 15 
 1 
5.3 The workforce and the health divide 2 
Expansion of nurses’ roles might ensure timely access to medicines, reduce waiting times 3 
and hospital admissions, and be a more prudent use of healthcare resources and a positive 4 
addition to clinical practice (Stenner & Courtenay, 2008; Health Education England, 2018). 5 
However, nurse-prescribing depends on support, and strong multi-disciplinary relationships 6 
(Creedon et al., 2015, Bowen et al., 2017). These are only available in well-staffed practice 7 
areas. 8 
 9 
Role expansion has been viewed as the only realistic option to deal with increased demands 10 
for healthcare (Department of Health, 2001), mainly for the old and poor. The creation of a 11 
distinct class of non-specialist health care professional to administer medicines to the poor, 12 
equivalent to the Russian feldsher, has not been openly considered since the formulation of 13 
medical registration in 1858 (Hart, 1988). However, a higher proportion of prescription 14 
items are initiated by nurses in areas of socio-economic deprivation (rho 0.19) and where 15 
the number of GPs/ 100,000 population falls below 60 (rho -0.16) (Drennan et al., 2014). 16 
However, our data indicate that not all nurses are willing to expand their roles, and caveats 17 
were raised at interview, including the problem of incompatible medicines from multiple 18 
prescribers with no clear overall responsibility. To reassure the public, future work should 19 
explore whether burgeoning health inequalities might be related to the disproportionate 20 
number of nurse prescribing and expanded-role developments providing services formerly 21 
undertaken by doctors in places unattractive to doctors, such as rural areas, former coal-22 
mining communities and other areas of economic deprivation (Jordan, & Griffiths 2004). 23 
 24 
5.4 Strengths and limitations 25 
Mixed methods research has a long tradition (Hesse-Biber, 2015), driven, in part, by 26 
philosophical pragmatism prioritising solutions to real-world problems (Dewey 1938). The 27 
synergy achieved by combining narratives and numbers contributes to understanding social 28 
phenomena. This work is framed in pragmatic terms (Misak, 2011): we need a reliable 29 
solution to the practical problem of medicines optimisation in a system characterised by 30 
shortages and inequalities.  Whilst we acknowledge the risks of dissonance in 31 
methodological eclecticism (Teddlie & Tashokkori, 2012), and the risks of subverting either 32 
 16 
data set (O’Cathain et al., 2008), the convergence and complementarity of findings 1 
outweigh the constraints of paradigm dissonance (Denzin, 2012). 2 
 3 
 Like all self-reported data, both survey and interview data were vulnerable to social 4 
desirability, recall, and volunteer biases and respondent error (Campanelli, 2008). Our 5 
survey response rate was disappointing, and we attribute this to our method of 6 
questionnaire distribution (McColl, Jacoby, & Thomas, 2001; Edwards, Roberts, & Clarke, 7 
2007; AAPOR, 2016), and the delays in obtaining governance approvals. There were low 8 
numbers of respondents in some categories, offering only general indications of trends. The 9 
age, sex and length of service of survey respondents are in line with the profile of UK nurses 10 
(Royal College of Nursing, 2018). However, respondents were self-selected, and might 11 
represent the more highly educated and motivated.  12 
 13 
We acknowledge the hazards of multiple testing, and have limited inferential analyses 14 
accordingly; however, as all analyses are indicating the same general trend, we are not 15 
basing our interpretations on any single P values (Rothman, 1990). We have no reason to 16 
assume that our Trusts / UHBs are atypical of non-metropolitan UK, but we make no claim 17 
that our respondents represent random samples. We would not wish to make statistical 18 
generalisations beyond this sample (Altman 1991), but the data offer signposts and 19 
suggestions as to addressing the ‘ADR problem’ that is causing 5-8% of unplanned 20 
admissions (NICE, 2015), including notes of caution regarding universal or compulsory 21 
expansion of nurses’ roles. 22 
 23 
6 | CONCLUSION 24 
The scale and complexity of inadvertent iatrogenic harm from the use and misuse of 25 
prescribed medicines demand change (WHO 2017) and the closure of the ‘care gaps’  26 
pinpointed here. The solution is seen as effective team-working, but workforce and financial 27 
constraints suggest this can only be achieved by expanding pharmacists’ and nurses’ roles. 28 
However, without structure, patients will continue to be left over-medicated, with 29 
preventable ADRs, including hypotension, constipation, sedation, confusion and dyspnoea, 30 
as reported here and elsewhere (Jordan et al., 2019).  31 
 32 
 17 
If iatrogenic harm (and associated admissions) are to be reduced, medicines optimisation 1 
must be prioritised. Targeting well-educated nurses for structured interventions to monitor 2 
patients offers a practical solution to suboptimal medicines management. To ensure that 3 
this reallocation of the division of labour does not further disadvantage areas of socio-4 
economic deprivation, role expansion must be accompanied by multidisciplinary support 5 
and ministry-level programme changes to reduce ADRs, polypharmacy and 6 
miscommunication, as recommended by the WHO (2017).  7 
 8 
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TABLE 1: THEMATIC ANALYSIS (Quotations selected to illustrate data themes) 
 Themes  
Tasks  Unoccupied professional territory, and need for change Nurse education as a barrier Workloads and time 
pressures as a barrier 
ADR monitoring Doctors think nurses monitor: 
“You prescribe that but you would expect that the nurse 
would not give it if the blood pressure was really low.  Just 
like with things like painkillers, making sure they wouldn’t 
give it if there were signs of toxicity. … you’re putting a lot of 
trust down to the nurse that’s giving the medication that 
they will make the sensible decision … a very significant 
amount of responsibility for it.” (England doctor Acute). 
“If I’ve started a medication I expect them [nurses] to tell me 
if it has made any difference” (England, doctor, nursing 
home) 
 
Pharmacists felt nurses should be monitoring: 
“They [nurses] should be looking for adverse effects and 
making sure the medicines are working for the patients” 
(England, pharmacist, nursing homes) 
 
Nurse thinks doctors monitor: 
“I'm a firm believer that if you prescribe a drug, it is your 
responsibility to follow up to see whether the outcome is of 
benefit to the patient.  So I think the primary responsibility 
for a follow up should be with the prescriber.” (England, 
Community nurse),  
“I think the physicians have to provide information and 
instruction to the nurses. (Acute nurse Wales). 
 
And it’s not done: 
“Some of the nurses, they take all the vital signs, the 
blood pressure, the weight, the MUST scores and they 
do nothing with it. (…) take those residents with very 
high blood pressure, and I’m like so what have you done 
“Nurses may lack knowledge, so that is a weakness - 
their drug knowledge. And the fact that they should 
be aware of what they’re administering, what 
they’re giving to the patient, that they should have 
an idea of what it is” (…) Weaknesses of the nurses’ 
roles in medication management is their knowledge.  
… nurses aren’t as knowledgeable when they’re 
coming into practice.  … they’re coming into practice 
having to learn.  So whilst I might have learnt and 
trained many years ago, I felt I came out with a very 
good basic knowledge. …  nurses may lack that 
knowledge, and they really should be aware of what 
they’re giving to that patient. They should have an 
idea about what it is. … there’s no reason why this 
can’t happen in the university.” (Acute nurse Wales) 
 
Results of inadequate education: 
“I went into a nursing home and they hadn’t given 
Macrogol, which is a laxative, originally on the 
medication administration record as PRN, so they 
hadn’t given the Macrogol for 10 days, they just 
kept writing not required, not required. And then on 
the 11th day they give an enema. (...) then you see 
things like loperamide on the MAR chart and you see 
Movicol on the MAR chart, ‘cause maybe the 
patient had an issue once and they were given 
loperamide out of hours, they carried on over and 
over -.” (England, pharmacist, Nursing home) 
 
 
“I think nurses do struggle 
sometimes to access 
ongoing education because 
they’re busy and can’t be 
let off practice.” (England, 
Pharmacist, community) 
 
“I think they would benefit 
from some kind of annual 
teaching on medications” 
(England, pharmacist, 
mental health).  
 
Time pressures in the 
nursing curriculum: “bigger 
part of their [nurses] 
training being based on 
pharmacology” (England, 
doctor, acute) 
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 Themes  
Tasks  Unoccupied professional territory, and need for change Nurse education as a barrier Workloads and time 
pressures as a barrier 
about this, have you let the GP know?  Oh no, not yet.  
And then so why do you bother taking the blood 
pressure readings if you don’t--, if you don’t have 
anything to do with it--, if you’re not going to do 
anything with it?” (England, pharmacist, nursing homes) 
• “Its a fundamentally important job and one that’s all too 
often missed particularly on the health promotion side” 
(Wales, nurse, mental health) 
• “As doctors we hand it out for hypertension and then we 
don’t hear about the side effects. And then the nurse will 
say, oh such and such is having problems with her feet, 
such and such is having problems with her shoes. It’s 
that missing link, you know, there’s a side effect, should 
we be changing our prescription based on those 
findings? and then you would say who would find those 
things out? And it would tend to be the nursing staff” 
(Wales, doctor, acute) 
“…nebulisers when people are wheezy.  The amount 
of times I've got called and then you just think, okay 
they’re wheezy, they need a nebuliser - but the 
nurses being able to identify that ... an area for 
improvement.” (England, doctor, acute) 
 
 “Most times they just give what is on the list 
and the patient might be suffering from a side 
effect of the medication. I would say nine times 
out of ten, they don’t pick up that they 
shouldn’t still be giving this medication.” 
(England, pharmacist, Nursing home) 
 
Adherence 
monitoring 
A problem raised in mental health: 
“I see people coming back to my ward time and time again, 
very, very unwell. It’s very distressing for them and their 
family, lost years of their lives, and the ongoing burden of 
increased treatment [high] doses, not to mention the burden 
of those frequent relapses all because they didn’t take their 
tablets. And did we do everything we could have to prevent 
that? No we didn’t.” (Wales, nurse, mental health) 
 
“I am aware that there are actually standardised 
approaches to talking to patients to improve their 
adherence to prescribed medication regimes. But, 
it’s within the competence of any trained nurse to do 
that work” (England, doctor, mental health) 
 
No comments 
Nurse prescribing Where nurses were working in previously unoccupied 
professional territory, prescribing was an important 
component: 
“if your in a specialist role or you’re an advanced nurse 
practitioner, you know independent prescribing is a real key 
to your success” (Wales, nurse, acute care)  
“some of them [nurses] I believe are not very 
confident with medication” (England, Pharmacist, 
nursing home) 
 
“Sometimes nurse prescribers can get drawn into 
roles that go beyond their competence. For example, 
I supervise a nurse prescriber in my community 
“Actually having nurse 
prescribers is potentially 
the answer [to current lack 
of medical staff] but that 
takes them away from their 
current duties” (England, 
doctor, mental health)  
 28 
 Themes  
Tasks  Unoccupied professional territory, and need for change Nurse education as a barrier Workloads and time 
pressures as a barrier 
“with independent nurse prescribing you generally have a 
nurse who’s prescribing and been in that set role, or is very 
mature in practice, or has been in that role for several years 
so they have lots to add in terms of skillset.” (Wales, nurse, 
acute)  
 
Role confusion centred on overcrowding of professional 
territory, rather than a gap: 
“Within prescribing, having several people given free range 
to prescribe, is the sort of recipe for disaster in general, 
regardless of who it is” (Wales, nurse, acute)  
“It could become chaotic and therefore unsafe and we could 
lose control, is the principal fear and therefore lead to 
prescribing practices that are unregulated, unsafe and not 
monitored.” (England, doctor, mental health)  
”We lose control of prescribing costs.” (England, doctor, 
community).   
 
“The GPs, when you speak with them, they are furious and 
like - can you imagine a nurse calling me to give conjunctivitis 
drops --, which you can buy over the counter.  So the GPs 
moan, the nurses moan that GPs are not responding fast, and 
find it ridiculous.” (England, pharmacist, nursing home) 
 
mental health team and one thing I often check are 
people asking you to do things like provide a 
diagnosis, provide a risk assessment, because 
actually if a nurse is asking you to do that you are 
[supposedly] no more trained to do that than they 
are.” (England, doctor, mental health) 
 
 
 
“Nurses are already pretty 
busy with their own roles 
at the moment and they 
may not want to take on an 
additional role” (Wales, 
doctor, Community)  
“actually having enough 
nurses to cover the 
essentials before they take 
on these extended roles” 
(England, Pharmacist, 
mental health)  
 
“... when you’re 
interrupted constantly, 
you’re trying to write a 
drug chart, you’re trying to 
re write a drug chart, trying 
to prescribe, you’re in a 
pressured environment 
that can obviously happen 
sometimes, errors can be 
made” (England, nurse, 
acute) 
 
Patient education  
“when you’r giving out medication its making sure that you 
do tell the patient what they are, what drugs they are taking, 
often I think we forget to do that so, yeah, making sure, 
because they [patients] question” (England, nurse, acute) 
 
Nurses lacked the knowledge themselves: 
“They [nurses] don’t seem to have much knowledge 
about individual drugs when they come out of 
university so it’s probably a steep learning curve for 
them when they start as a newly qualified nurse.” 
(England, pharmacist, acute) 
“In terms of education, 
again I think nurses should, 
they have an opportunity, 
more than doctors, to 
educate” (Wales, doctor, 
community) 
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Tasks  Unoccupied professional territory, and need for change Nurse education as a barrier Workloads and time 
pressures as a barrier 
“I think there are a lot of nurses out there who don’t go far 
enough” (Wales, doctor, community) 
 
“Patient education and information varies between 
individuals and nursing homes, how competent the 
nurse is on that. Some of them don’t even know 
what the medication is used for so they wouldn’t be 
in a good position to. But all I can say, it varies, it all 
depends on individual, but the majority I have come 
across, I wouldn’t… (…) Certainly they [nurses] need 
to be able to know what medicines are for, what side 
effects they have and give that information when 
they speak to patients.” (England, pharmacist, 
nursing home) 
“If they [patients] ask them [nurses] why they are 
taking medications they [nurses] should be able to 
say why” (England, doctor, nursing home) 
 
 
Note: From 2019, nurse prescribing will be taught in the UK within the preregistration education programme (Nursing & Midwifery standards, 
2018). Newly qualified nurses and midwives will be deemed “prescriber ready”, and, if working in areas of clinical need, able to access post-
registration prescribing programmes, including Community Nurse Prescribing (V150), and Independent Prescribing (V300) within one year of 
qualification (Nursing & Midwifery Council, 2018).  
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Table  2: Medicines optimisation roles and nurse education 
 
 Nurses’ involvement 
should be extended 
in: 
What is your highest educational level as a 
nurse? 
Total n(%) Unadjusted 
analysis 
Adjusted analyses Other significant variables 
Diploma or 
below n(%) 
Bachelors 
n(%) 
Masters 
n(%) 
PhD 
n(%) 
Χ2 
df 1 
 
P value aOR (95% CI) 
Bachelors 
aOR 
(95% CI) 
Maters 
aOR (95% 
CI) 
PhD 
ADR monitoring 22/ 44 (50) 54/ 100 (54) 33/52 
(63.5) 
13/14 
(92.9) 
122/210 
(58.1) 
7.25 0.01 1.18 (0.58-
2.41) 
1.67 
(0.73-
3.83) 
13.00 
(1.56-
108.01) 
none 
Medication 
adherence 
20/ 39 
(51.3) 
48/94 (51.1) 31/48 
(64.6) 
11/14 
(78.6) 
110/195 
(56.4) 
4.38 0.04 1.13 (0.53-
2.44) 
1.83 
(0.75-
4.45) 
3.55 (0.84-
14.97) 
Gender female 0.28 (0.08-1.04) 
Prescribing 24/34 (70.6) 52/88 (59.1) 33/46 
(71.7) 
11/13 
(84.6) 
120/181 
(66.3) 
1.21 0.27 0.60 (0.24-
1.48)a 
0.94 
(0.32-
2.71) a 
3.10 (0.54-
17.59) a 
Working with: 1-4 pharmacists 
2.10 (1.09-4.03): >4 pharmacists 
3.14 (0.33-29.58) 
Patient education 23/35 (65.7) 51/87(58.6) 35/46 
(76.1) 
12/13 
(92.3) 
121/181 
(66.9) 
4.54 0.03 0.79 (0.35-
1.80) 
1.72 
(0.68-
4.65) 
6.26 (0.73-
54.08) 
none 
 
ADR adverse drug reaction, aOR, adjusted odds ratio, CI confidence interval, LL log likelihood 
 
a  not in final model 
note: not all respondents gave their education achievements in the 4 categories analysed, and could not be included in these analyses.  
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Table  3: Nurses’ experience of medicines monitoring 
 
 Wales n(%) England 
n(%) 
Wales 
n(%) 
England 
n(%) 
Wales 
n(%) 
England 
n(%) 
 Wales 
n(%) 
England 
n(%) 
Did you monitor any 
patients for side effects 
and therapeutic effects 
during the last month? 
Did you monitor 
medication adherence for 
any patients during the 
last month? 
Did you prescribe  
medication for any 
patients during last the 
month? 
 Did you provide patient 
education/information 
about medication use 
during the last month? 
Yes 89 (69.5) 61 (66.3) 86 (67.2) 52 (56.5) 33 (25.8) 8 (8.7)  94 (73.4) 55 (59.8) 
No 34 (26.6) 27 (29.3) 32 (25.0) 26 (28.3) 78 (60.9) 62 (67.4)  17 (13.3) 16 (17.4) 
No answer 5 (3.9) 4 (4.3) 10  (7.8) 14 (15.2) 17 (13.3) 22 (23.9)  17 (13.3) 21 (22.8) 
If yes, which 
statements apply? 
 
Last time you observed a 
side effect, what did you 
do (more answers 
possible): 
n(%) 
Last time you observed a 
side effect, what did you 
do (more answers 
possible): 
n(%) 
Last time you observed 
non-adherence in a 
patient, what did you 
do? (more answers 
possible): n(%) 
Questions relating to patient education.  
If yes, which statements apply?  
 
 
I discussed it with a 
doctor  
103 (80.5) 69 (75) 92 (71.8) 57 (62.0) 76 (59.4) 49 (53.3) Pharmacists, physicians and nurses were well 
aware of patient education/information 
provided by each team member 
38 (29.7) 20 (21.7) 
I discussed it with a 
pharmacist 
35 (27.3) 16 (17.4) 22 (17.2) 14 (15.2) 35 (27.4) 19 (20.6) I felt qualified to provide patient education or 
information about medication use 
73 (57) 38 (41.3) 
I discussed it with a 
nurse 
48 (37.5) 34 (36.9) 38 (29.7) 34 (37.0) 36 (28.1) 24 (26.1) I received enough information from the doctor 
to provide patient education or information 
about medication use 
26 (20.3) 17 (18.5) 
I discussed it with a 
patient 
67 (52.3) 42 (45.6) 78 (60.9) 48 (52.2) 29 (22.7) 17 (18.5) I feel other professionals would have given 
better patient education or information about 
medication use 
20 (15.6) 6 (6.5) 
I reported it in the 
patient file 
68 (53.1) 38 (41.3) 68 (53.1) 38 (41.3) 35 (27.3) 15 (16.3) None of the above answers 4 (3.1) 0 
I intervened on my 
own initiative (eg. 
Stopping 
medication 
administration) 
47 (36.7) 27 (29.4) 24 (18.8) 20 (21.7) 23 (18.0) 8 (8.7)    
I did nothing 0 1 (1.1) 1 (0.8) 0 3 (2.3) 2 (2.2)    
I have never 
observed a side 
effect 
7 (5.5) 7 (7.6) 9 (7.0) 8 (8.7) 21 (16.4) 14 (15.2)    
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Table  4: The current situation in medicines monitoring 
 Agree 
strongly 
n(%) 
Agree 
n(%) 
Don’t 
Know 
n(%) 
Disagree n(%) Disagree 
strongly 
n(%) 
No 
response 
n(%)  
If I need a doctor to discuss a patient’s medicines management 
/optimisation or pharmaceutical care, he/she is easily available 
for collaboration/ discussion (Question only for nurses) 
Wales Nurses 32 (25) 69 (53.9) 4 (3.1) 13 (10.2) 5 (3.9) 5 (3.9) 
England Nurses 24 (26.1) 45 (48.9) 5 (5.4) 11 (11.9) 3 (3.3) 4 (4.3) 
If I need a pharmacist to discuss a patient’s medicines 
management / optimisation or pharmaceutical care, he/she is 
easily available for collaboration/ discussion. 
Wales  Nurses  31 (24.2) 69 (53.9) 7 (5.5) 13 (10.1) 3 (2.3) 5 (3.9) 
England  Nurses  13 (14.1) 46 (50) 16 (17.4) 6 (6.5) 7 (7.6) 4 (4.3) 
My employers’ policies stimulate inter-professional medicines 
management.  
Wales Nurses 21 (16.4) 74 (57.8) 14 (10.9) 12 (9.4) 2 (1.6) 5 (3.9) 
Doctors  1 (11.1) 3 (33.3) 3 (33.3) 2 (22.2) 0 0 
Pharmacists 10 (23.8) 25 (59.5) 3 (7.1) 4 (9.5) 0 0 
England Nurses 10 (10.9) 52 (56.5) 12 (13.0) 13 (14.1) 1 (1.1) 4 (4.3) 
Doctors  0 3 (37.5) 0 3 (37.5) 1 (12.5) 1 (12.5) 
Pharmacists 10 (50) 4 (20) 1 (5) 5 (25) 0 0 
 
 
